FDA clears Edesa Biotech IND for Phase 2 vitiligo drug study

October 15, 2026 9:15 AM

Edesa Biotech, Inc. (Nasdaq: EDSA) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found